Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Clinical Trials, CVS Caremark Corporation, Drugs (Pharmaceuticals), Eli Lilly and Company, GLP-1 RAs (Drug), Health Insurance and Managed Care, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Research
←Transportation Secretary Gets Pressed Over Repeated Airport Failures And Musk’s FAA Cuts
Johnny Rodriguez, Country Music Star, Dead at 73→

More posts

  • Disney Offers $20M For Character.AI Assets As Startup Files For Chapter 11 Bankruptcy Protection

  • Trump has asked Kimberly Guilfoyle to resign, White House says

  • Controversial ‘Downstate’ Delays First Broadway Preview Due To Illness

  • Getting Booked: Here’s What 5 Models Read Backstage During the Spring 2027 Season

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube